Ivermectin and COVID-19
J Infect
.
2025 Jun 8;91(2):106530.
doi: 10.1016/j.jinf.2025.106530.
Online ahead of print.
Authors
Christopher C Butler
1
,
Fd Richard Hobbs
2
,
Paul Little
3
,
Duncan Richards
4
,
Benjamin R Saville
5
,
Ly-Mee Yu
6
;
PRINCIPLE Trial Collaborative Group
6
Affiliations
1
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: christopher.butler@phc.ox.ac.uk.
2
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: richard.hobbs@phc.ox.ac.uk.
3
Primary Care Research Centre, University of Southampton, UK.
4
Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK.
5
Berry Consultants, Austin, TX, USA; Department of Biostatistics, Vanderbilt University School of Medicine, TN, USA.
6
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
PMID:
40494426
DOI:
10.1016/j.jinf.2025.106530
No abstract available
Publication types
Letter